✦ LIBER ✦

Clinical pharmacokinetic studies on factor VIII and factor IX – experiences from the Malmö centre

✍ Scribed by S. BJÖRKMAN

Book ID: 108772646
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 418 KB
Volume: 12
Category: Article
ISSN: 1351-8216
DOI: 10.1111/j.1365-2516.2006.01328.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prophylactic dosing of factor VIII and f

Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective

✍ S. Björkman 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

**Summary.** The high cost and limited availability of factor concentrates make dosing of factor VIII (FVIII) or factor IX (FIX) a crucial issue in the prophylactic treatment of haemophilia. It has often been recommended that this treatment should aim to maintain a minimum plasma level of 1% of norm

The diagnosis and management of factor V

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation

✍ Charles R. M. Hay; S. Brown; P. W. Collins; D. M. Keeling; R. Liesner 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

THE DIAGNOSIS and MANAGEMENT OF FACTOR V

THE DIAGNOSIS and MANAGEMENT OF FACTOR VIII and IX INHIBITORS: A GUIDELINE FROM THE UK HAEMOPHILIA CENTRE DOCTORS' ORGANIZATION (UKHCDO)

✍ C. R. M. Hay; T. P. Baglin; P. W. Collins; F. G. H. Hill; D. M. Keeling 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB

Soluble syndecan-1 level at diagnosis is

Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival

✍ Richard Lovell; Janet A. Dunn; Gulnaz Begum; Nicola J. Barth; Tim Plant; Paul A. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB